פרסומים והרצאות

הרצאות

Link	Conference	Title
	VITA NOVA 2021 Meeting, Bratislava, Slovakia, 21.10.2021.	LH supplementation in ovarian stimulation for IVF: The individual, LH deficient, patient perspective.
https://youtube.com/watch?v=jryOKljxDCg&list=PLNiWLB_wsOg4VAfCi9ciCO4NLcp2DXO8W&t=19s&index=3	Tel Aviv University, An Update in Fertility Treatments Symposium, June 15th, 2018.	The endocrinology of the luteal in IVF.
	Tel Aviv University, February 21, 2020.	Natural pregnancy in advanced age (Hebrew).
	XII International Congress on Reproductive Medicine, Moscow, Russia, 16-19.1.2018.	A novel look at luteal phase support post IVF.
	The «6th Congress of the Hellenic Society of Fertility & Sterility». Thessaloniki, Greece, May 28-30, 2021, Satellite Symposium 1: Connecting the details for life.	A wider spectrum in FSH and LH deficiency.
	Update in Ob/Gyn, Leumit Sick Fund, Dead Sea, Israel, October 9, 2015.	Management of fertility treatment in PCOS patients.
http://www.youtube.com/watch?v=5plZs_hcYMY		Radio interview: “The experts”, Haifa Radio, June 6th, 2017
https://hcp.merckgroup.com/en/academe/expert-opinion/shahar-kol.html	Buenos Aires Argentina, March 2022.	To add LH or not to add LH during ovarian stimulation
https://www.youtube.com/watch?v=imqEalV_0so&authuser=1	November 17th, 2017.	LH supplementation in antagonist protocol
	Potruguese Fertility Society Annual meeting, Merck symposium. September 24, 2021.	LH and FSH deficiency: personalization of controlled ovarian stimulation treatment.
	ESHRE Campus, Madrid, Spain, 3 December 2010.	Does GnRHa triggering completely abolish OHSS? GnRH agonist for triggering of final oocyte maturation – time for a paradigm shift.
	Israel Fertility Association, School of Reproductive Endocrinology, April, 2016.	IVF treatment of high responders.
	Merck organised European Fertility Meeting (PERSONALISING THE PATIENT Journey in ART to SHORTEN TIME TO LIVE BIRTH) November 24th-25th, 2017 at Sheraton Congress Hotel, Frankfurt, Germany.	Reducing implantation failure: novel approach to luteal phase support.
	Tartu. Estonia, 20.10.23.	LH supplementation in IVF: It is all about endocrinology.
	The 10th Annual Meeting of the Israeli Society for Community Gynecology, Israel, October 17, 2007.	Advanced age fertility: Can we improve the results?
	WOOSP 2014, Jaipur India, August 6-10, 2014.	Recombinant LH, recombinant hCG and GnRH agonist to trigger ovulation in antagonist cycles: a critical Evaluation.
	WOOSP 2014, Jaipur India, August 6-10, 2014.	Luteal support post agonist trigger for OHSS prevention: The introduction of “luteal coasting” as a novel approach.
		Regulatory guidelines for IVF: HBV and HCV infected individuals.
	11th Internatinal Symposium on GnRH, February 9-11, 2014, Salzburg, Austria.	Individualized treatment from theory to practice: the private case of adding LH during GnRH antagonist based stimulation protocol.
	IVF Worldwide online congress, October 1-3, 2021.	Progesterone free luteal support in IVF.
	Maccabi Health Care, March 2016.	Quality measurement in IVF
https://istudy.co.il/emed/mod/page/view.php?id=2670		I-study: Continued medical education, Fertility: Ovulation triggering methods, and luteal phase support, first part.
https://www.youtube.com/watch?v=i2oVztWdYws	World Congress on Women’s Health Innovations and Inventions (WHII): Addressing Unmet Needs. July 9-11, 2019 Tel Aviv, Israel.	Endometrial receptivity can be improved with luteal support fine-tuning. 1st
	Research Day, Maccabi-Assuta, Tel Aviv, January 2016 (Hebrew).	IVF results in Maccabi Health Services 2011-2014.
	Merck Mini-Symposium, Chateau du Lac, Genval, Belgium 4.10.2021.	Severe LH and FSH deficiency in an infertile patient undergoing ART.
	Asia Pacific COGI conference, Bangkok, Thailand, November 2011.	OHSS: Should this be treated or prevented?
		TV interview: IVF results in Israel, March 9th, 2016.
		IVF 2020, Maccabi Health Care, February 2014.
https://youtu.be/xk406W-q7OE	IVF Worldwide Webinar Series, April 6, 2020.	The endocrinology of the luteal phase in IVF cycles (Hebrew)
	Hillel Yafe, Hadera Israel, March 2014.	GnRH agonist and individualized luteal phase hCG support will avoid OHSS in PCOS. Toward friendly stimulation in Assisted Reproductive Technology.
	17th Annual conference of Indian Fertility Society, FERTIVISION 2021, 10th-12th December, 2021.	Progesterone-free luteal support for IVF.
	9th International IVIRMA Congress, Spain, Virtual Congress Week, November 15-19, 2021.	Poor prognosis patients and LH: from RCT’s and metanalyses to personalized medicine.
	EXCEMED, Improving success in ART, Tallinn, Estonia, 19 October 2019. (plenary).	What kind and dose of gonadotropins to use? Are biosimilars an option?
	Athens, Greece, July, 2023.	Individualized LH supplementation in ovarian stimulation for IVF: Just a slogan or a reality.
	The World Association of Perinatal Medicine, Novel approaches in Fertility and Ovulation, Dead Sea, Jordan, May 25th, 2019 (plenary).	Prevention of OHSS: Modern Technique.
	The World Association of Perinatal Medicine, Novel approaches in Fertility and Ovulation, Dead Sea, Jordan, May 25th, 2019 (plenary).	Treatment strategies in infertile PCOS.
	Ho Chi Minh City, Vietnam, November, 2022.	LH supplementation and ART: For whom?
	Turkish Society of Reproductive Medicine (TSRM): Evidence based approach in ART. September 17, 2022, Ankara, Turkiye.	Individualized LPS: Fresh and FET cycles.
	Ferring Excahnges in Fertility (Scientific Committee), September 29-30, 2022, Copenhagen, Denmark.	hCG as trigger: The good the bad and the alternative.
	Serono Symposia, St. Petersburg, Russia, May 5-6, 2006.	Prevention of OHSS.
	COGI 2015, Frankfurt, Germany, May 14-16, 2015.	Luteal coasting post GnRH agonist trigger.
	COGI conference, Singapore, July 2012.	GnRH-a to trigger ovulation should be used in all PCOS patients to prevent OHSS.
	WOOSP 2014, Jaipur India, August 6-10, 2014.	Elonva in poor responders.
	11th Internatinal Symposium on GnRH, February 9-11, 2014, Salzburg, Austria.	OHSS prevention: Yes, we can!
	COGI 2014, Ho Chi Minh City, Vietnam, November 20-22, 2014.	Treatment strategies for the infertile PCO patient.
https://istudy.co.il/emed/mod/page/view.php?id=2671		I-study: Continued medical education, Fertility: Ovulation triggering methods, and luteal phase support, second part.
https://vimeo.com/329865501/073c64c4e8		Working together with the Jewish Fertility Foundation.
	Updates in Infertility Treatment, Budapest, Hungary, 8-10 February, 2012.	Prevention of OHSS.
	Israel Fertility Society meeting, January 2019.	The luteal phase: a new era.
	ESHRE Campus, Brussels, December 10th, 2004.	GnRH agonist instead of hCG to trigger ovulation in GnRH antagonist cycles.
	Cappadocia, Turkiye, May 2023.	Time to personalize luteal phase support – fresh and FET cycles.
	EXCEMED, Improving success in ART, Tallinn, Estonia, 19 October 2019. (plenary).	Triggering for ovulation – What are the options (hCG, GnRH a, Dual Triggering)?
	Carmel Hospital, Haifa, Israel, October 2014.	IVF in Israel, quality vs. quantity.
	Sociedade Portuguesa de Medicina da Reprodução. Porto, Portugal, May 10, 2019 (plenary).	The roadmap to LH supplementation in IVF.
https://ivf.co.il/%D7%A8%D7%93%D7%99%D7%95%20%D7%A7%D7%95%D7%9C%20%D7%97%D7%99%20151020.mp3		Radio Kol Chai interview October 15, 2020 (Hebrew)
	25th Brazilian Congress on Assisted Reproduction and 15th Red Latinoamericana de Reproducción Assistida, November 5, 2021.	To add LH or not to add LH? Is this a personal question?

פרסומים

Link	Authors	Journal	Title
	Kol S, Itskovitz-Eldor J.	Hum Reprod. 15:2266-7, 2000.	Severe OHSS: yes, there is a strategy to prevent it!
https://www.fertstert.org/action/showPdf?pii=S0015-0282%2803%2902705-5	Kol S.	Fertil Steril 81:1-5, 2004.	Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.
	Barnea ER, Fares F, Kol S.	Placenta 10:37, 1989.	Stimulatory effect of prolactin on human placental progesterone secretion at term in vitro: possible inhibitory effect on estradiol secretion.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/andr.12533	Kol S.	Andrology. 2018;6:662-664.	Ultra-Orthodox Jews and infertility diagnosis and treatment.
	S. Kol P. Humaidan.	Science Repository, published: August 22, 2022.	Luteinizing Hormone and Ovarian Stimulation for In-Vitro Fertilization: Do Science and Business Always Agree?
https://www.annalsthoracicsurgery.org/article/0003-4975(93)91010-K/pdf	Kol S, Ammar R, Weisz G, Melamed Y.	Ann Thorac Surg, 55:401, 1993.	Hyperbaric oxygenation for arterial air embolism during cardiopulmonary bypass.
	Adir Y, Bitterman H, Kol S, Melamed Y.	Israel Journal of Medical Sciences 27:669, 1991.	Hyperbaric oxygen treatment for carbon monoxide intoxication acquired in the sealed room during the Persian Gulf War.
https://www.rbmojournal.com/action/showPdf?pii=S1472-6483%2817%2930569-2	Lawrenz B, Humaidan P, Kol S, Fatemi HM.	Reprod Biomed Online. 2018;36:75-77.	GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?
https://www.rbmojournal.com/article/S1472-6483(10)61663-X/pdf	Kol S, Muchtar M.	Reproductive BioMedicine Online 10:575-577, 2005.	Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further reseach.
	Weiner F, Kanter Y, Kol S, Barzilai D.	Meth Inform Med 21:191, 1982.	Computer implementation of the new diabetes classification scheme.
https://link.springer.com/article/10.1007/s10815-025-03758-1	Marina Marks Kazatsker, Shahar Kol, Samer Khoury	Journal of Assisted Reproduction and Genetics 2025	Mechanical luteinization of follicles before oocyte retrieval is often overlooked: a case report
	Kol S, Itskovitz-Eldor J.	Hum. Reprod. 20:2362, 2005.	Society’s contribution to assisted reproductive technology abuse.
	P. Humaidan, B. Alsbjerg, H.O. Elbaek, B.B. Povlsen, R.J. Laursen, M.B. Jensen, A.T. Mikkelsen L.H. Thomsen, S. Kol, T. Haahr.	Reprod Biomed Online, 2021;42:1108-1118.	The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients.
	Humaidan P, Kol S and Papanikolaou EG, on behalf of the ‘The Copenhagen GnRH Agonist Triggering Workshop Group’.	Human eproduction Update 2011 ;17:510-524.	GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
	Itskovitz-Eldor J, Kol S Mannaerts B.	Hum Reprod 15:1965-1968, 2000.	Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication.
	Weissman A, Kol S, Peretz BA.	J Reprod Med 41:103-111, 1996.	Gas embolism in obstetrics and gynecology.
	Kol S.	Gynecol Obstet Invest. 2020;85:307-311.	LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective.
	Kol S.	Israel, Maariv, 23.2.1998.	First surrogacy pregnancy and delivery
https://pmc.ncbi.nlm.nih.gov/articles/PMC2582114/pdf/10815_2008_Article_9198.pdf	Kol S, Solt I.	Journal of Assisted Reproduction and Genetics 25:63-66, 2008.	GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?
	Kol S, Karnieli E, Kraiem Z, Itskovitz-Eldor J, Lightman A, Ish-Shalom S.	Gyncol Obstet Invest 42:227-229, 1996.	Thyroid function in early normal pregnancy: transient suppression of thyroid stimulating hormone, and stimulation of triiodothyronine.
	Kol S.	Human Reproduction 21:1328, 2006.	GnRH agonist trigger: looking for the coin under the lamp post?
	Lewit N, Kol S, Manor D, Itskovitz-Eldor J.	Gynecol Endocrinol 9 (Suppl) 4:13-17, 1995.	The Use of GnRH Analogues For the Induction of Preovulatory Gonadotropin Surge In Assisted Reproduction and Prevention of Ovarian Hyperstimulation Syndrome.
https://www.rbmojournal.com/action/showPdf?pii=S1472-6483%2810%2900440-2	Kol S, Humaidan P.	Reproductive BioMedicine Online 21:590-592, 2010.	LH (as hCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango.
https://www.fertstert.org/action/showPdf?pii=S0015-0282%2803%2900177-8	Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J.	Fertil Steril 79:1123-8, 2003.	Lower levels of inhibin A and pro- alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin.
	Kol S.	Edited by Gerris, Olivennes, Delvingne, Taylor&Francis. 2006	Does ovulation triggering influence the risk of OHSS? In “Ovarian Hyperstimulation Syndrome. Chapter 20.
	Kol S, Ben-Shlomo I, Ando M, Adashi EY.	Mol Hum Reprod 1997, 3:1095-1099.	Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression and activity.
	Orvieto N, Segal Y, Kol S.	Harefuah, March 2024 (Hebrew).	In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2015-2020.
	Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, and Itskovitz-Eldor J.	Hum Reprod 14:2242-2244, 1999.	High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze–thaw cycles .
https://journals.sagepub.com/doi/10.1177/26334941251369710	Samer Khoury, Raoul Orvieto and Shahar Kol	Therapeutic advances in reproductive health 2025, Vol. 19: 1–3	Vaginal progesterone for luteal phase support in frozen embryo transfer cycles: does it deliver?
https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0412.2012.01399.x	Kol S, Homburg R, Alsbjerg B, Humaidan P.	ACTA Obstetrica et Gynecologica Scandinavica 91:643-7, 2012.	The gonadotropin-releasing hormone antagonist protocol – the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
	Kol S, Ruutiainen K, Ben-Shlomo I, Ando M, Payne DW, Adashi EY.	Endocrinology 1997;138:322- 331.	The Rat Ovarian Phospholipase A2 System: Gene Expression, Cellular Localization, Activity Characterization, and Interleukin-1 Dependence.
	Kol S, Lewit N, Itskovitz-Eldor J.	Hum Reprod 11:1143, 1996.	Ovarian Hyperstimulation Syndrome after using Gonadotropin-releasing Hormone Agonist as a Trigger of Ovulation: Causes and implications.
	Itskovitz-Eldor J, Kol S.	In: Reproductive Endocrinology, Surgery and Technology. Adashi EY, Rock JA, Rosenwaks Z Editors, Raven Press, NY (1996).	Disorders of the gonadotrophs.
https://ijhpr.biomedcentral.com/articles/10.1186/s13584-016-0072-9	Kol S, Bergovoy Yellin L, Segal Y and Porath A.	Israel Journal of Health Policy Research 5:14, 2016. DOI: 10.1186/s13584-016-0072-9.	In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2007-2014.
	Kent-First MG, Kol S, Muallem A, Manor D, Blazer S, First N, Itskovitz-Eldor J.	Mol Hum Reprod 2:943-950, 1996.	The incidence and possible relevance of Y-linked microdeletions in ICSI derived babies and their infertile fathers.
	Kol S, Tannus S, Lightman A, Itskovitz J.	Harefuah 153:155-158, 2014.	Assisted reproductive technology in the presence of chronic viral disease.
https://joe.bioscientifica.com/view/journals/joe/160/3/415.xml	Derman SG, Kol S, Ben-Shlomo I, Resnick CE, Rohan RM, Adashi EY.	J Endocrinol 160:415-423, 1999.	Transforming growth factor-beta1 is a potent inhibitor of interleukin-1beta action in whole ovarian dispersates.
	Lightman A, Kol S, Itskovitz-Eldor J.	Hum Reprod 14:2596-2599, 1999.	A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles.
	Itskovitz-Eldor J, Kol S, Mannaerts B, Coelingh Bennink H.	Hum Reprod 13:294-5, 1998.	First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462).
https://www.sciencedirect.com/science/article/pii/S0015028216585847?via%3Dihub	Lewit N, Kol S, Itskovitz-Eldor J.	Fertil Steril 66:654, 1996.	Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome?
	Shuchat S, Park S, Kol S, Yossifon G.	Electrophoresis. 2019;40:1606-1614.	Distinct and independent dielectrophoretic behaviour of the head and tail of sperm and its potential for the safe sorting and isolation of rare spermatozoa.
	Kol S.	Fertil Steril. 2008, 89(1):260.	Ultrasound-guided embryo transfer – a special role in patients with certain uterine defects.
	Kanter Y, Kol S, Weiner F.	Eur J Obstet Gynecol Reprod Biol. 27:307, 1988.	Intravenous glucose tolerance test in gestational diabetes and pregnancy: manual vs. computerized assessment.
	Kol S, Ruutiainen-Altman K, Scherzer WJ, Ben-Shlomo I, Ando M, Rohan RM, Adashi EY.	Mol Cell Endocrinol 149:115-28, 1999.	The rat intraovarian interleukin (IL)-1 system: cellular localization, cyclic variation and hormonal regulation of IL-1beta and of the type I and type II IL-1 receptors.
	Kol S, Castillo J, Trolice MP, Quaas AM.	J Assist Reprod Genet. 2024,41:1715–1717.	Monitoring of controlled ovarian stimulation in IVF.
https://www.rbmojournal.com/action/showPdf?pii=S1472-6483%2815%2900430-7	Kol S, Breyzman T, Segal L, Humaidan P.	Reprod Biomed Online. 31:747-751, 2015.	‘Luteal coasting’ after GnRH agonist trigger – individualized, HCG-based, progesterone-free luteal support in ‘high responders’: a case series.
	Scherzer WJ, Putowski LT, Kol S, Adashi EY, Rohan RM.	J Soc Gyn Invest 1996;3:131-9.	Detection and In Vitro Hormonal Regulation of Rat Ovarian Type I and Type II Interleukin-1 Receptor mRNA: Increased Expression During the Periovulatory Period.
https://www.sciencedirect.com/science/article/pii/S0015028216553394?via%3Dihub	Nachum Z, Kol S, Adir Y, Melamed Y.	Fertil Steril 58:836, 1992.	Massive air embolism – a possible cause of death after operative hysteroscopy using a 32% dextran 70 pump.
	Kol S, Humaidan P.	Curr Opin Obstet Gynecol. 2021 1;33:188-195	IVF and the exogenous progesterone-free luteal phase.
	Kol S, Rohan RM and Adashi EY	The Global Library of Women’s Medicine. (2008)	The role of growth factors in ovarian function and development.
	Itskovitz-Eldor J, Levron J, Kol S.	Clin Obstet Gynecol, 36:701, 1993.	Use of GnRH-agonist to cause ovulation and prevent ovarian hyperstimulation sundrome.
	Shupak A, Melamed Y, Ramon Y, Bentur Y, Abramovich A, Kol S.	Arch Neurol 54:305-311, 1997.	Helium and oxygen treatment of severe air diving-induced neurologic decompression sickness.
	Kol S.	Med Hypotheses. 2008 Jan 10.	The vanishing follicle in women aged over forty: Premature, mechanical, LH-independent luteinization may reflect oocyte-follicle low quality?
https://rmmj.org.il/userimages/671/1/PublishFiles/718Article.pdf	Segal L, Fainaru O, Kol S.	Rambam Maimonides Medical Journal 8:21, 2017.	Anovulatory Patients Demonstrate a Sharp Decline in LH Levels upon GnRH Antagonist Administration during IVF Cycles.
	Kol S, Itskovitz-Eldor J.	In: Serono Symposia. Ovulation: Evolving Scientific and Clinical Concepts. Eli Y. Adashi, Editor. Springer-Verlag, New York, Inc. 2000, pp. 308-316.	Triggering ovulation with GnRH analogs.
	Castillo J, Kol S.	Curr Opin Obstet Gynecol. 2024, 1;36:148-154.	Ideal frozen embryo transfer regime.
https://www.jbc.org/article/S0021-9258(18)51921-9/fulltext	Payne DW, Shackeleton C, Toms H, Ben-Shlomo I, Kol S, deMoura M, Strauss JF, Adashi EY.	Biol Chem 270:18888-96, 1995.	A novel nonhepatic hydroxycholosterol 7ahydroxylase that is markedly stimulated by interleukin-1b J
	Humaidan P, Kol S.	Curr Opin Obstet Gynecol. 2021 1;33:213-217	Suboptimal response to GnRH agonist trigger: causes and practical management.
	Kol S, Jakobi P, Paldi E.	Harefua 118:676, 1990.	The intrauterine device, a transitional period.
	Kol S.	The Global Library of Women’s Medicine.(2011)	Ovarian hyperstimulation prevention.
	Kol S, Fainaru O.	Reproductive Medicine International 2018;1:1-2.	Inadvertent use of depot GnRH agonist trigger and its effect on the luteal phase. A case report.
	Kol S, Wong KH, Ando M, Ben-Shlomo I, Adashi EY.	Endocrine 11:269-75, 1999.	Rat ovarian interleukin-1alpha: interleukin-1-dependent in vitro expression.
	Kol S, Donesky BW, Ruutiainen-Altman K, Ben-Shlomo I, Irahara M, Ando M, Rohan RM, Adashi EY.	Biol Reprod 61:274-282, 1999.	Ovarian Interleukin-1 Receptor Antagonist in Rats: Gene Expression, Cellular Localization, Cyclic Variation, and Hormonal Regulation of a Potential Determinant of Interleukin-1 Action.
	Irahara M, Ando M, Kol S, Adashi EY.	J Reprod Immunol 45:67-79, 1999.	Expression and hormonal regulation of rat ovarian interleukin-1beta converting enzyme, a putative apoptotic marker: endocrine- and aracrine-dependence.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3230134/pdf/1477-7827-9-147.pdf	E.G Papanikolaou, P.Humaidan, N. Polyzos, S Kalantaridou, Kol S, C. Benadiva, H.Tournaye, B. Tarlatzis.	Reproductive Biology and Endocrinology 2011, 9:14.	New algorithm for OHSS prevention.
	Kol S, Ben-Shlomo I, Ando M, Payne DW, Adashi EY.	Endocrinology 1997;138: 314-321.	Interleukin-1b Stimulates Ovarian Phospholipase A2 (PLA2) Expression and Activity: Up-regulation of Both Secretory and Cystosolic PLA2.
https://www.fertstert.org/action/showPdf?pii=S0015-0282%2814%2900050-8	Mousavi Fatemi H, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, García-Velasco JA.	Fertil Steril. 101:1008-11, 2014.	Severe ovarian hyperstimulation after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze all” approach in GnRH antagonist protocol.
	Kol S, Homburg R.	Human Reproducion 23:1004-6, 2008.	Change, change, change: hormonal actions depend on changes in blood levels.
https://www.rbmojournal.com/article/S1472-6483(10)60046-6/pdf	Kol S, Dor J.	Reproductive BioMedicine Online 19:59-60, 2009.	Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation.
https://www.sciencedirect.com/science/article/pii/S001502821656049X?via%%203Dihub	Kol S, Levron J, Lewit N, Drugan A, Itskovitz-Eldor J.	Fertil Steril 60:127, 1993.	The natural history of multiple pregnancies after assisted reproduction: Is spontaneous fetal reduction a clinically significant phenomenon?
https://www.rbmojournal.com/action/showPdf?pii=S1472-6483%2815%2900485-X	Kol S, Breyzman T.	Reprod Biomed Online. 32:132-134, 2016.	GnRH agonist trigger does not always cause luteolysis: a case report.
	Itskovitz-Eldor J, Kol S, Lewit N, Sealey JE.	J Clin Endocrinol Metab 82:461-464, 1997.	Ovarian origin of plasma and peritoneal fluid prorenin in early pregnancy and in patients with ovarian hyperstimulation syndrome.
	Manor D, Kol S, Lewit N, Lightman A, Stein D, Pillar M, Itskovitz-Eldor J.	Hum Reprod 11:2502-2506, 1996.	Undocumented embryos: Do not trash them, FISH them.
	Kol S, Ben-Shlomo I, Adashi EY, Rohan RM.	Gen Alalysis 1996;12:129-132.	Simplified riboprobe purification using starslucent straws as gel tubes.
	Kol S, Adashi EY.	Current Opinions in Obstetrics and Gynecology, 7:209, 1995.	Intra-ovarian factors regulating ovarian function.
	Kent-First MG, Kol S, Muallem A, Blazer S, Itskovitz-Eldor J.	Lancet 348:332, 1996.	Infertility in intracytoplasmic-perm-injection-derived sons.
	Kol S.	Gynecol Obstet Invest. 2019;84:1-5.	A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger.
	Ando M, Kol S, Irahara M, Sirois J, Adashi EY.	Mol Cell Endocrinol 157:21-30, 1999.	Non-steroidal anti-inflammatory drugs (NSAIDs) block the late, prostanoid-dependent/ceramide-independent component of ovarian IL-1 action: implications for the ovulatory process.
https://www.fertstert.org/action/showPdf?pii=S0015-0282%2800%2900574-4	Beloosesky R, Kol S, Lightman A, Itskovitz-Eldor J.	Fertil Steril 74:166-8, 2000.	Ovarian stimulation in in vitro fertilization with or without the “long” gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome.
https://rmmj.org.il/userimages/661/0/PublishFiles/661Article.pdf	Kol S, Fainaru O.	Rambam Maimonides Medical Journal 8:23, 2017.	GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care Campus.
	Kol S, Gordon CR, Melamed Y.	Intensive & Critical Care Digest 12:48, 1993.	The potential role of oxygen in the prevention of neurologic deficit after cardiac surgery.
https://journals.sagepub.com/doi/full/10.1177/26334941251379935	Shahar Kol, Samer Khoury	Therapeutic advances in reproductive health 2025, Vol. 19: 1–3	Luteal phase support after hCG trigger: does it support or mitigate hCG-induced potential harms?
	Eshet S, Milner E, Segal L, Monzer A, Kol S.	Harefuah. 2017 Oct;156:670.	In vitro fertilization (ivf) treatment for viral diseases carriers: summary of treatment outcome of hiv-positive patients.
	Kol S.	Human Reproduction Update, advanced access published March 31, 2006.	Agonist trigger in the context of OHSS prevention: primum non nocere.
	Kol S, Humaidan P, Itskovitz-Eldor J.	Hum. Reprod. 26:2874-77, 2011.	GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
	Aharon-Peretz J, Adir Y, Gordon CR, Kol S. Gal N, Melamed Y.	Arch Neurol 50:753, 1993.	Spinal Decompressionsickness in sport diving.
	Kol S, Ben-Shlomo I, Ando M, Adashi EY.	Mol Hum Reprod 3:1095-9, 1997.	Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression and activity.
	Kol S.	Medicine and Law 19:74-77, 1998.	Oocyte donation: the shortage and a possible solution.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4213184/pdf/cmrh-8-2014-059.pdf	Kol S.	Clinical Medicine Insights: Reproductive Health 8:59–64, 2014.	Individualized Treatment from Theory to Practice: The Private Case of Adding LH during GnRH Antagonist-based Stimulation Protocol.
	Itskovitz-Eldor J, Filmar S, Manor D, Stein D, Lightman A, Kol S.	Gyncol Obstet Invest 43:73- 75, 1997.	Assisted implantation: Direct intra-endometrial embryo transfer.
	Kol S, Humaidan P, Alsbjerg B, Engmann L, Benadiva C, García-Velasco JA, Fatemi H, Andersen CY.	Reproductive BioMedicine Online 30:563–565, 2015.	The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors.
	Kol S.	Human Reproduction 20:3257, 2005.	Luteal support post GnRH agonist trigger: do not stop too soon.
	Tannus S, Burke YZ, Kol S.	Womens Health (Lond Engl). 11:901-12, 2015.	Treatment strategies for the infertile polycystic ovary syndrome patient.
	Ben-Shlomo I, Kol S, Roeder LM, Resnick CE, Hurwitz A, Payne DW, Adashi EY.	Endocrinology 1997;138:2680-2688.	Interleukin (IL)-1b Increases Glucose Uptake and Induces Glycolysis in aerobically Cultured Rat Ovarian Cells: Evidence that IL-1b may Mediate the Gonadotropin- Induced Midcyle Metabolic Shift.
	Evron A, Blumenfeld Z, Adashi E, Kol S	Glob. libr. women’s med., (ISSN: 1756-2228) 2015; DOI 10.3843/GLOWM.10288.	The Role of Growth Factors in Ovarian Function and Development.
	Kol S.	Fertil Steril 79:1466, 2003.	Vascular endothelial growth factor – mediator of PHSS?
	Kol S.	Encyclopedia of Endocrinology and Endocrine Diseases. Editor-in-Chief Luciano Martini, 2004, Academic Press, San Diego. California.	Assisted Reproductive Technology.
	Kol S.	Hum Reprod; 5:1881-1882, 2000 Webtrack (12.6.2000).	GnRH antagonists in ART: lower embryo implantation?
	R. Homburg, Kol S	Human Reproduction, doi:10.1093/humrep/den307.	Letter to the Editor: Reply: Investigating actions of changing hormone levels.
	Itskovitz-Eldor J. and Kol S.	Washington Post, February 20, 1997.	Fertilization method is linked to gene defect.
https://www.tandfonline.com/doi/full/10.1080/14767058.2026.2641844	Alexander M. Quaas, Juan Carlos Castillo Farfán, Mark P. Trolice, Gillian Mackay & Shahar Kol	The Journal of Maternal-Fetal & Neonatal Medicine Volume 39, 2026 - Issue 1	Effects of prior cesarean delivery on subsequent pregnancy outcomes using assisted reproductive technology: a narrative review
	Levron J, Zinchenko V, Kol S, Direnfeld M, Bider D.	Gynecol Endocrinol. 30:755-7, 2014.	The use of portable CO2 incubator for cross-border shipping of embryos in an international egg donation program.
	Ando M, Kol S, Kokia E, Ruutiainen-Altman K, Sirois J, Rohan RM, Payne DW, Adashi EY.	Endocrinology 139:2501-8, 1998.	Rat ovarian prostaglandin endoperoxide synthase-1 and -2: periovulatory expression of granulosa cell-based interleukin-1-dependent enzymes.
	Hershkop E, Segal L, Fainaru O, Kol S.	Reprod Biomed Online. 34:274-279, 2017.	‘Model’ versus ‘everyday’ patients: can randomized controlled trial data really be applied to the clinic?.
https://www.fertstert.org/article/S0015-0282(25)01869-2/abstract	Shahar Kol, Samer Khoury	Fertil Steril Volume 124, Issue 6p1342-1343 December 2025	Comment on “gonadotropin-releasing hormone antagonist protocol is associated with higher oocyte yield in young women at high risk for low oocyte retrieval” Shahar Kol, M.D.a ∙ Samer Khoury, M.D.a,b
https://www.fertstert.org/article/S0015-0282(97)81371-4/pdf	Lightman A, Kol S, Wayner V, Vertman D, Manor D, Itskovitz-Eldor J.	Fertil Steril 67:711-6, 1997.	The presence of a sponsoring embryo in a batch of poor quality thawed embryos significantly increases pregnancy and implantation rate.
https://www.rbmojournal.com/article/S1472-6483(10)61680-X/pdf	Kol S.	Reproductive BioMedicine Online 11:664-666, 2005.	To add or not to add LH: consideration of LH concentration changes in individual patients.
	Kol S, Weisz G, Melamed Y.	Aviat Space Environ Med 64:236, 1993.	Pulmonary barotrauma after a free dive – a possible mechanism.
	P. Humaidan, S. Kol, E.G. Papanikolaou, L. Engmann, C. Benadiva, J. Itskovitz-Eldor, E.J. Margalioth, E. Ricciarelli, D. Bodri, J.C. Castillo-Farfan, J.A. Garcia-Velasco, C. Yding Andersen, P. Devroey and B. Tarlatzis.	Hum. Reprod. Update 2012 18: 229-230.	Reply: GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data.
	Sella T, Segal Y, Goren I, Chodick G, Shalev V, Homburg R, Bachar R, Kol S.	Harefuah 152:11-14, 2013.	In-Vitro fertilization cycles and outcomes in Maccabi Healthcare Services in Israel 2007-2010.
	P. Humaidan, Kol S, L. Engmann, C. Benadiva, E.G. Papanikolaou, and C. Yding Andersen, on behalf of the Copenhagen GnRH Agonist Triggering Workshop Group.	Hum. Reprod. 27:6-8, 2012.	Should Cochrane reviews be performed during the development of new concepts?
	Kol S.	Letter to the Editor. Fertil Steril. 96:e151, 2011.	A case of severe early-onset OHSS after GnRH-agonist triggering.
	Kol S, Humaidan P.	Reproductive BioMedicine Online 26: 226– 230, 2013.	GnRH agonist triggering: recent developments.
	Tannus S, Burke Y, McCartney CR, Kol S.	Gynecol Endocrinol. 25:1-5, 2017.	GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism.
	Kol S.	Hum Reprod.18:1557-8. 2003.	Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!
	Kol S, Gal D, Friedman M, Paldi E.	TVS and CA-125. Gynecologic Oncology 37:129, 1990.	Case report: preoperative diagnosis of fallopian tube carcinoma by
	Vanetik S, Segal L, Breizman T, Kol S.	Gynecol Endocrinol. 2018;34:132-135.	Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger – a proof of concept study.
	Adir Y, Kol S, Melamed Y.	Harefuah, 122:249, 1992.	Carbon monoxide and coronary artery disease.
https://www.ima.org.il/FilesUploadPublic/IMAJ/0/200/100026.pdf	Fainaru O, Kol S.	Isr Med Assoc J. 18:364, 2016.	How Many Embryos Should Be Transferred? The Relevance of Parity and Obstetric History.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8129594/pdf/deab065.pdf	E. Bosch, C. Alviggi, M. Lispi, A. Conforti, A.C. Hanyaloglu, D. Chuderland, M. Simoni, N. Raine-Fenning, P. Cre´ pieux, S. Kol, V. Rochira, T. D’Hooghe, and P. Humaidan.	Human Reproduction, 2021. 17;36:1469-1480	Reduced FSH and LH action: implications for medically assisted reproduction.
	Kol S, Segal L.	Reproductive Biomedicine Online. 2020;41:854-858.	GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte retrieval for luteal phase support.
	Kol S.	Elsevier. 17-Oct-2014 doi:10.1016/B978-0-12-801238-3.03880-0.	Assisted Reproductive Technology (ART), Reference Module in Biomedical Sciences.
	Lewit N, Kol S, Manor D, Itskovitz-Eldor J.	Hum Reprod 11:1399, 1996.	Comparison of GnRH Analogs And Hcg For The Induction of Ovulation And Preventation of Ovarian Hyperstimulation Syndrome (OHSS): A Case-control Study.
	Barnea ER, Perlman R, Fakih H, Bick T, Kol S, Hochberg Z.	Acta Endocrinologica 121:767, 1989.	The role of catecholamines in estradiol and progesterone secretion by cultured explants and cells of human term placenta.
	Kol S.	Manual of ovulation induction; ovarian stimulation protocols, 3rd edition. Editors: Allahbadia and Merchant. Jaypee Brothers Medical Publishers, 2016.	LH and FSH surges for final oocyte maturation: Is dual surge beneficial?.
https://www.fertstert.org/action/showPdf?pii=S0015-0282%2800%2900599-9	Lewit N, Kol S.	Fertil Steril 74:401-2, 2000.	The low responder female IVF patient with hypogonadotropic hypogonadism: do not give up!
	Barnea ER, Simon RJ, Kol S.	Placenta 10:331, 1989.	Human embryonal extracts modulate placental function in the first trimester: effect of visceral tissues upon chorionic gonadotropin and progesterone secretion.
	Kol S, Lewit N, Itskovitz-Eldor J.	Mid East Fertil Soc J 1:246, 1996.	Ovarian hyperstimulation syndrome: modern concepts in pathophysiology and management.
	Kol S.	Hum Reprod. 16:595-6, 2001.	Should we explore OHSS full clinical scope?…
	Vanetik S, Beck-Fruchter R, Segal L, Kol S.	Gynecol Obstet Invest. 2020;85:184-188.	The Importance of Mid-Follicular Phase Luteinizing Hormone Rise in GnRH Antagonist-Based Ovarian Stimulation for IVF.
https://academic.oup.com/humrep/article/33/1/177/4582787?login=false	Kol S, Gal M.	Hum Reprod. 2018 1;33:177.	False positive blood hCG test following Corifollitropin alfa injection.
	Ben-Shlomo I, Kol S, Ando M, Altman KR, Putowski LT, Rohan RM, Adashi EY	Biol Reprod 1997;57:217-225.	Ovarian expression, cellular localization, and hormonal regulation of rat secretory phospholipase A2: increased expression by interleukin-1 and by gonadotropins.
	Kol S, Rohan RM and Adashi EY	In: Sciarra JJ (Ed.), Gynecology and Obstetrics, Lippincott Williams and Wilkins, Philadelphia, PA. Vol. 5, 11:1-13. (2000)	The role of growth factors in ovarian function and development.
https://www.rbmojournal.com/action/showPdf?pii=S1472-6483%2815%2900376-4	Segal L, Breyzman T, Kol S.	Reproductive BioMedicin	Luteal phase support post IVF: individualized early stop.
	Kol S, Ben-Shlomo I, Ruutianen K, Ando M, Resnick CE, Rohan RM, Adashi EY.	J Clin Invest 1997, 99:2274-2283.	The midcycle increase in ovarian glucose uptake is associated with enhanced expression of glucose transporter 3.
	Kol S, Ben-Shlomo I, Payne DW, Ando M, Rohan RM, Adashi EY.	Mol Cell Endocrinol 137:117-25, 1998	Glucocorticoids suppress basal (but not interleukin-1-supported) ovarian phospholipase A2 activity: evidence for glucocorticoid receptor-mediated regulation.
	Kol S.	Medicine and Law 15:59, 1996.	Medical examination of rape victims.
	Kol S, Itskovitz-Eldor J.	Semin reorod Med 28:500-505, 2010.	Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome–a 20-year experience.
	Barnea ER, Ashkenazy R, Tal Y, Kol S, Sarne Y.	Hum Reprod 6: 1327, 1991.	Effect of b-endorphin on human chorionic gonadotrophin secretion by placental explants.
	Jakobi P, Kol S, Weissman A, Krivoy N.	J Reprod Med 37:127, 1992.	Peripartum changes in free and protein bound digoxin like immuno-reactive factor.
	Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R.	Hum. Reprod. 27:753-9, 2012.	Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.
	Coffler MS, Kol S, Drugan A, Itskovitz-Eldor J.	Hum Reprod 14:1875-1878, 1999.	Early transvaginal embryo aspiration: a safer method for selective reduction in high order multiple gestations.
	S. Kol.	Gynecological Endocrinology. 2021;37:775-777.	Time, time time: see what governs the luteal phase endocrinology.
	Kol S, Thaler I, Paz N, Shmueli O.	Am J Obstet Gynecol 172:1372, 1995.	Interpretation of nonstress tests by an artificial neural network.
	Kol S.	In: “Contemporary Endocrinology: Hormone Replacement Therapy”, second edition. Editor: Wayne Meikle, pp 525-536, 2003, Humana Press, Totowa, NJ.	Hormonal Therapy of the Infertile Woman.
	Kol S, Kehat I, Adashi EY.	Med Hypotheses. 58:6-8, 2002.	Ovarian interleukin-1-induced gene expression: privileged genes threshold theory.
	J. Castillo, S. Kol.	Reproductive Biomedicine Online , 2023, Nov;47(5):103324	Time-sensitive assessment of luteal phase progesterone after hCG ovulation triggering: Another brick off the wall?
	Castillo J, Quaas AM, Kol S.	J Assist Reprod Genet. 2024;41:609-612.	LH supplementation in IVF: human nature, politics, and elephants in the room.
	Kol S, Adir Y, Gordon CR, Melamed Y.	Undersea Biomed Res 20:147, 1993.	Oxy-helium treatment of severe spinal decompression sickness after air diving.
	Kol S, Adir Y, Shupak A, Stahl S.	Techniques in Hand and Upper Extremity Surgery 2:274-277, 1998.	Adjuvant hyperbaric oxygenation therapy in hand edema and ischemia.